ArticleJournal of managed care & specialty pharmacy2024

US cost-utility model of lenacapavir plus optimized background regimen (OBR) vs fostemsavir plus OBR and ibalizumab plus OBR for people with HIV with multidrug resistance.

Vittoria Vardanega et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.